Navigation Links
Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/18/2007

CAMBRIDGE, England, October 18 /PRNewswire/ -- Astex Therapeutics Ltd. today announced that data on two of its drug candidates, AT7519 and AT13148, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held October 22-26, 2007 in San Francisco.

AT7519 is a potent and selective Cyclin Dependent Kinase (CDK) inhibitor currently in multi-centre Phase 1 clinical trials. AT13148 is a potent and selective inhibitor of AKT and certain other AGC kinases, which is in pre-clinical development.

AT7519 and AT13148 are among five compounds currently being developed by Astex for the treatment of solid tumours and haematological malignancies. All of the compounds were discovered by Astex using its proprietary fragment-based drug discovery platform Pyramid(TM).

"With fewer than 100 people engaged in drug discovery and development at Astex, we have generated a development pipeline of five novel products in less than five years and put two of those products into clinical trials," said Leon Bushara, Chief Executive of Astex. "That record of productivity is a testament to the power of our drug discovery technology, the strength and focus of our organisation, and the ingenuity of our scientists. Going forward, we expect to introduce at least one new product into development every year."

In addition to AT7519 and AT13148, Astex is developing:

- AT9283, a multi-targeted inhibitor of Aurora kinases, JAK2 and BCR-Abl, currently in multiple Phase 1 and Phase 1/2 multi-center clinical trials;

- AT13387, a selective inhibitor of Hsp90, for which Astex will file, during the fourth quarter of 2007, an Investigational New Drug (IND) application with the FDA to start clinical trials; and

- AT9311, a selective, orally administered, inhibitor of CDKs, partnered with Novartis.

Astex also has five internal drug discovery programmes and is pursuing another six projects in partnership with leading pharmaceutical companies including Novartis, AstraZeneca, Bayer Schering and Boehringer Ingelheim.

Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Poster Title: A comparison of the pharmacological profile of AT7519 in solid tumor and hematological cell lines.

--------------------------------------------------------------------

Session Date : Tuesday, October 23, 2007, 12:30 PM

Session Title : Poster Session A

Session Subtitle : Small Molecule Therapeutic Agents: Kinase

Inhibitors

Session Time : 12:30-2:30 PM and 5:30-7:30 PM

Session Location : Exhibit Hall, First Floor, Moscone Convention

Center West

Abstract Number : A247

--------------------------------------------------------------------

Poster Title: AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation.

--------------------------------------------------------------------

Session Date : Wednesday, October 24, 2007, 12:30 PM

Session Title : Poster Session B

Session Subtitle : Small Molecule Therapeutic Agents: Kinase

Inhibitors

Session Time : 12:30-2:30 PM and 5:30-7:30 PM

Session Location : Exhibit Hall, First Floor, Moscone Convention

Center West

Abstract Number : B251

--------------------------------------------------------------------

About Astex

Astex Therapeutics is a biotechnology company that discovers and develops novel small molecule therapeutics. Using its pioneering fragment-based drug discovery platform Pyramid(TM), Astex has built a pipeline of five molecularly-targeted oncology drugs, of which two are currently being tested in clinical trials and three are in pre-clinical development.

In addition to its proprietary research programmes, Astex's unprecedented productivity in lead discovery has been endorsed through numerous partnerships with major pharmaceutical companies, including Novartis, AstraZeneca, and Boehringer Ingelheim.

For further information on Astex Therapeutics please visit the Company's website at http://www.astex-therapeutics.com

Web: http://www.astex-therapeutics.com


'/>"/>
SOURCE Astex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. What citizens dont ask political candidates
2. Candidates sparring over jobs focuses debate on right issue
3. To find solid security candidates, look beyond tech certificates
4. Presidential candidates stretch necks and facts
5. Innovation featured in NE Wisconsin Roundtable
6. Madison music featured on Internet radio station
7. Wisconsin biotech sector featured in scientific magazine
8. The Information Age of Healthcare - Leaders featured on local new economy show
9. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
10. Olympics of biotechnology has international flavor
11. Traffic data firm navigates international business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Biostage, Inc. (Nasdaq: ... developing bioengineered organ implants to treat cancers and other ... today the closing on February 15, 2017 of its ... stock and warrants to purchase 20,000,000 shares of common ... offering was priced at $0.40 per share of common ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... Series 1a financing and entered into a $5 ...  Dermata intends to use the capital for general ... major advancements in the treatment of serious diseases ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... extended its industry leading Biochemistry Services specifically targeting the rapidly growing needs ... methods for the biochemical and biosimilar characterization , product-related impurity characterization, ...
Breaking Biology Technology:
(Date:2/3/2017)... A new independent identity strategy consultancy firm announces its ... to fill a critical niche in technical and policy ... Mark Crego and Janice Kephart together ... that span federal governments, the 9/11 Commission, private industry, ... has a common theme born from a shared passion ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, a ... emerging technology, announces the availability of a new report, Sensors ... Continue Reading ... ... and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
Breaking Biology News(10 mins):